

Shang-Ju Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764916/publications.pdf>

Version: 2024-02-01

62
papers

2,421
citations

218662

26
h-index

206102

48
g-index

62
all docs

62
docs citations

62
times ranked

3732
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. <i>Bone Marrow Transplantation</i> , 2022, 57, 95-105.	2.4	8
2	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	1.3	8
3	Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2022, 101, 349-358.	1.8	12
4	Phosphoproteomics Reveals the Role of Constitutive KAP1 Phosphorylation by B-cell Receptor Signaling in Chronic Lymphocytic Leukemia. <i>Molecular Cancer Research</i> , 2022, 20, 1222-1232.	3.4	1
5	Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. <i>Journal of Hematology and Oncology</i> , 2022, 15, 56.	17.0	4
6	Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7500-7500.	1.6	19
7	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	7.2	40
8	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. <i>Journal of the Formosan Medical Association</i> , 2021, 121, 643-643.	1.7	1
9	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Blood</i> , 2021, 138, 128-128.	1.4	13
10	Successful treatment of nasal-type extra-nodal natural killer/T cell lymphoma with simultaneous involvement of the thyroid, liver, and pancreas. <i>Annals of Hematology</i> , 2019, 98, 2243-2246.	1.8	2
11	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	3.7	29
12	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>BMC Cancer</i> , 2019, 19, 617.	2.6	43
13	Distinctive incidence patterns of follicular lymphoma in Taiwan: Implications of ethnic differences. <i>Cancer Medicine</i> , 2019, 8, 1899-1907.	2.8	6
14	Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. <i>British Journal of Haematology</i> , 2019, 186, 72-85.	2.5	11
15	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	3.7	11
16	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor risk factor in <i>de novo</i> acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2018, 101, 86-94.	2.2	31
17	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	4.1	75
18	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. <i>Clinical Epigenetics</i> , 2018, 10, 42.	4.1	36

#	ARTICLE	IF	CITATIONS
19	Concerted mass spectrometry-based glycomic approach for precision mapping of sulfo sialylated N-glycans on human peripheral blood mononuclear cells and lymphocytes. <i>Glycobiology</i> , 2018, 28, 9-20.	2.5	24
20	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. <i>EBioMedicine</i> , 2018, 37, 91-100.	6.1	54
21	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 87.	6.2	34
22	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . <i>Haematologica</i> , 2018, 103, e510-e513.	3.5	29
23	Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2310-2315.	2.0	4
24	Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications. <i>Haematologica</i> , 2017, 102, 1085-1090.	3.5	21
25	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2017, 7, 663.	6.2	39
26	Morphometric analysis of erythrocytes from patients with thalassemia using tomographic diffractive microscopy. <i>Journal of Biomedical Optics</i> , 2017, 22, 1.	2.6	3
27	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	7.3	38
28	Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan. <i>Annals of Hematology</i> , 2016, 95, 1727-1729.	1.8	3
29	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. <i>Scientific Reports</i> , 2016, 6, 36730.	3.3	18
30	A nationwide population-based cross-sectional comparison of hematological malignancies incidences between Taiwan and the United States of America. <i>Annals of Hematology</i> , 2016, 95, 165-167.	1.8	12
31	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). <i>Oncotarget</i> , 2016, 7, 63177-63188.	1.8	21
32	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 9084-9101.	1.8	77
33	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 49-49.	1.4	0
34	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0119831.	2.5	6
35	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. <i>PLoS ONE</i> , 2015, 10, e0137552.	2.5	7
36	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0128410.	2.5	50

#	ARTICLE	IF	CITATIONS
37	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. <i>BMC Cancer</i> , 2015, 15, 344.	2.6	48
38	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4956-4956.	1.4	0
39	The Osteoblastogenesis Potential of Adipose Mesenchymal Stem Cells in Myeloma Patients Who Had Received Intensive Therapy. <i>PLoS ONE</i> , 2014, 9, e94395.	2.5	9
40	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i> , <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. <i>American Journal of Hematology</i> , 2014, 89, 137-144.	4.1	76
41	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2014, 89, 181-186.	4.1	56
42	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. <i>American Journal of Hematology</i> , 2014, 89, E109-15.	4.1	34
43	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East. <i>Annals of Hematology</i> , 2013, 92, 799-806.	1.8	14
44	Clinical implications of <i>U2AF1</i> mutation in patients with myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2013, 88, E277-82.	4.1	56
45	Improving but Inferior Survival in Patients with Chronic Lymphocytic Leukemia in Taiwan: A Population-Based Study, 1990–2004. <i>PLoS ONE</i> , 2013, 8, e62930.	2.5	17
46	The clinical implication of <i>SRSF2</i> mutation in patients with myelodysplastic syndrome and its stability during disease evolution. <i>Blood</i> , 2012, 120, 3106-3111.	1.4	127
47	<i>DNMT3A</i> mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. <i>Blood</i> , 2012, 119, 559-568.	1.4	211
48	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. <i>Blood</i> , 2010, 115, 2749-2754.	1.4	193
49	<i>WT1</i> mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. <i>Blood</i> , 2010, 115, 5222-5231.	1.4	156
50	The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. <i>Blood</i> , 2010, 116, 4430-4435.	1.4	56
51	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (<i>ASXL1</i>) mutations. <i>Blood</i> , 2010, 116, 4086-4094.	1.4	187
52	Primary effusion lymphoma in three patients with chronic hepatitis B infection. <i>Journal of Clinical Virology</i> , 2009, 44, 81-83.	3.1	14
53	HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 423-427.	1.7	2
54	<i>AML1/RUNX1</i> Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations.. <i>Blood</i> , 2009, 114, 1564-1564.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Epidemiology of Chronic Lymphocytic Leukemia in Taiwan: The Incidence Trend and Its Comparison with That in Caucasian Americans.. <i>Blood</i> , 2009, 114, 4378-4378.	1.4	0
56	Clinical Characteristics and Treatment Response of Hodgkin's Lymphoma in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 4-12.	1.7	6
57	Anaplastic Large Cell Lymphoma in Leukemic Transformation: Successful Treatment by Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4490-4492.	1.6	2
58	Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. <i>Haematologica</i> , 2007, 92, 141-142.	3.5	39
59	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome “ the mutatan can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. <i>British Journal of Haematology</i> , 2007, 139, 405-414.	2.5	122
60	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2006, 135, 317-323.	2.5	32
61	<i>Nucleophosmin</i> Mutations in <i>De novo</i> Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. <i>Cancer Research</i> , 2006, 66, 3310-3316.	0.9	165
62	Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation.. <i>Blood</i> , 2006, 108, 561-561.	1.4	6